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Abstract 
 
Aims:Intravesical instillation of hyaluronic acid (HA) plus chondroitin sulfate (CS) in 
women with bladder pain syndrome/interstitial cystitis (BPS/IC) has shown 
promising results. This study compared the efficacy, safety, and costs of intravesical 
HA/CS (Ialuril®, IBSA) to dimethyl sulfoxide (DMSO).  
Methods:Randomized, open-label, multicenter study involving 110 women with 
BPS/IC. The allocation ratio (HA/CS:DMSO) was 2:1. Thirteen weekly instillations (3 
months) of HA(1.6%)/CS(2.0%) or 50% DMSO were given. Patients were evaluated at 
3 and 6 months. Prima y endpoint was reduction in pain intensity at 6 months by 
visual analogue scale (VAS) compared with baseline. Secondary efficacy 
measurements, quality of life, and economic analyses were assessed.  
Results:A significant reduction in pain intensity was observed at 6 months in both 
treatment groups versus baseline (P<0.0001) in the ITT population. Treatment with 
HA/CS resulted in a greater reduction in pain intensity at 6 months compared with 
DMSO for the PP population (mean VAS reduction 44.77±25.07 versus 28.89±31.14, 
respectively; P=0.0186). There were no significant differences between treatment 
groups in secondary outcomes. At least one adverse event was reported in 14.86% 
and 30.56% of patients in the HA/CS and DMSO groups, respectively. There were 
significantly fewer treatment-related adverse event for HA/CS versus DMSO (1.35% 
versus 22.22%; P=0.001). Considering direct healthcare costs, the incremental cost-
effectiveness ratio of HA/CS versus DMSO fell between 3735€/quality-adjusted life 
years (QALY) and 8003€/QALY.  
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Conclusions:Treatment with HA/CS appears to be as effective as DMSO with a 
potentially more favorable safety profile. Both treatments increased the quality of 
life, while HA/CS was more cost effective.  
 
 
Key words: Bladder pain syndrome; Chondroitin sulphate; DMSO; Hyaluronic acid; 
Interstitial cystitis; Ialuril 
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Introduction 
 
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic bladder 
condition(1, 2) characterized by pelvic pain, increased urinary frequency and 
urgency, in addition to high levels of sexual dysfunction, sleep disturbance, and 
impairment in quality of life(3, 4). Debilitating pelvic pain associated with BPS/IC is 
challenging to treat(2), and both physicians and patients may be unsatisfied with the 
quality of care(5). 
Although the precise etiology of BPS/IC remains unknown(6, 7), bladder 
urothelial dysfunction, bladder inflammation, neuropathic pain, and infection have 
been proposed as the main etiologies(8). Strong evidence suggests that 
pathophysiological disruption of the bladder mucosa surface leads to loss of 
glycosaminoglycans (GAGs)(9) exposing the urothelium to toxic agents or bacteria in 
urine causing alterations in the bladder wall(9, 10). This damage can trigger a 
cascade of inflammatory and neurogenic responses resulting in pain, problems in 
voiding, and chronic changes to the bladder(10-12).  
Accordingly, restoration of the urothelial barrier with exogenous GAG 
administration can help to re-establish its integrity in patients with BPS/IC(9, 13-16). 
In this regard, the combination of hyaluronic acid (HA) and chondroitin sulfate (CS) 
has shown promising results in small patient cohorts(17, 18), and has been 
confirmed for up to 3 years(11). 
Dimethyl sulfoxide (DMSO) is the only intravesical treatment for BPS/IC approved 
by the FDA and grade A recommended by the European Association of Urology 
(EAU).  This study compared intravesical treatment of HA/CS with DMSO in female 
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patients with BPS/IC to better understand its efficacy, safety, and direct/indirect 
healthcare costs.  
 
Materials and Methods 
 
Study design and patient population 
This was a phase III, randomized, controlled study (EudraCT 2010-021556-
25). An open-label design was adopted due to the garlic-like taste of DMSO after 
intravesical administration, which would have been impossible to mask.  
A total of 110 women were randomized to receive 13 weekly instillations (3 
months) of HA (1.6%) and CS (2.0%) (Ialuril®; IBSA) or 50% DMSO solution (RIMSO®; 
Bioniche), with a 2:1 allocation ratio (HA/CS:DMSO). A randomization scheme for the 
preparation of a centralized randomization procedure was generated by the Moses-
Oakford algorithm, using the procedure Etcetera of the software WinPEPI v.10. The 
study was conducted in accordance with the Declaration of Helsinki. All patients 
signed a written consent for participation in the study. The trial was performed at six 
centers in Italy and approved by the respective Ethics Committees. 
The study enrolled female patients aged 18 years or more with a diagnosis of 
BPS/IC, according to the ESSIC Criteria(19), unresponsive to first line non-invasive 
treatments or at first observation. Relevant inclusion criteria included the presence 
of pain (pelvic, pressure or discomfort) with at least one other urinary symptom such 
as urgency, increased urination frequency for at least 6 months, discomfort or pain 
during sexual intercourse. Pregnant or breastfeeding women, presence of other 
confusable diseases as the main cause of urinary symptoms, or those who had 
undergone previous intravesical treatments were excluded. A minimum time of 3 
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months from last treatment to start of therapy was required for all patients. A 
randomization visit, during which treatment was started, was carried out 15−20 days 
following the screening visit. The first patient was enrolled on 30 Jun 2011, and the 
last patient completed the study on 30 Sep 2013. 
 
Clinical assessments 
An initial screening visit was performed to determine patient eligibility and 
obtain informed consent. In addition to clinical examination and history, renal and 
vesical ultrasound scan was carried out in all patients; urodynamic test, 
cystourethroscopy, and vulvoscopy were performed at the discretion of the clinician. 
The primary endpoint was reduction in pain intensity, evaluated by a 0−100 visual 
analogue scale (VAS), at 6 months (i.e. after a treatment-free period of 3 months) 
compared with baseline. Responders were defined as those with at least 50% VAS 
reduction in pain from baseline. Secondary endpoints were reduction in pain 
intensity after the 3-month treatment period and changes from baseline in other 
urinary symptoms recorded using the O’Leary-Sant Interstitial Cystitis Symptom and 
Problem Index (ICSI/ICPI)(20), the Pelvic Pain and Urgency/Frequency Symptom 
Scale (PUF)(21), and a 3-day voiding diary. The EQ-5D-3L questionnaire, consisting of 
a health state index (EQ Index) and VAS for the patient’s self-rated health status (EQ 
VAS), was used to evaluate quality of life. The assessment of safety included the 
registration of all investigator-assessed adverse events (AEs). All study visits were 
carried out by a clinician. 
 
Statistical analysis 
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Sample size was calculated in terms of difference between treatments on VAS 
pain level from baseline to 6 months considering a medium-large effect size of 0.6 
with power ≥80% and α=0.05. Analysis of covariance (ANCOVA), with baseline as 
covariate, a modified baseline observation carried forward (mBOCF) approach to 
impute missing data in case of dropouts for lack of efficacy or adverse event, and a 
last observation carried forward (LOCF) strategy in case of dropouts for other 
reasons, were used to compare HA/CS and DMSO. The VAS score changes from 
baseline after 6 months (primary endpoint) were analyzed in the intention to treat 
(ITT) population, including all randomized patients, and in the per protocol (PP) 
population, including patients completing the study without any major protocol 
violation and without receiving any grade A/B recommended treatment for BPS/IC, 
according to EAU Criteria(22), within 3 months from inclusion or during the study. 
The secondary endpoints were analyzed in the ITT population, and safety endpoints 
in the safety population, including all patients who received at least one dose of 
treatment. SAS Software (release 9.4) was used for statistical analyses. A p value 
<0.05 was considered statistically significant. 
 
Economic evaluation 
The primary objective of the economic analysis was to evaluate the incremental 
cost-effectiveness ratio (ICER) of HA/CS versus DMSO over a period of 12 months 
after the start of therapy in the ITT population. No discounting was performed. The 
ICER was calculated by dividing the incremental costs by the incremental quality-
adjusted life years (QALY). Specific forms were designed to record data about direct 
healthcare resource consumption, productivity losses, and informal care. Direct 
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medical costs were estimated from the Italian National Healthcare Service 
perspective, including drugs, hospitalization, and exams. Unitary costs, expressed as 
euro (€) 2010, were derived from a previous publication(23). For productivity losses 
and informal care, gross hourly wages were derived from Italian National Institute of 
Statistics (ISTAT) tables(24). The utility scores, providing a single index value for 
health status ranging from 0 (death) to 1 (perfect health), were derived from the EQ 
Index, using a utility scoring function(25), to calculate QALY as the area under the 
utility profile over time. Since data were only collected up to 6 months, two different 
scenarios were considered in order to provide a one-year time span for the ICER 
calculation: an optimistic one, assumed the utility measured at 6 months would hold 
until 12 months, and a pessimistic one, assumed the utility values return to levels 
observed at baseline. No additional cost was imputed. Given the generalized small 
sample size in the dataset, statistical hypothesis testing was not attempted.  
 
Results 
Fig. 1 shows the CONSORT diagram of the study. A total of 110 women were 
screened, 74 for HA/CS and 36 for DMSO, with a mean age of 50.2 years (range 
18−88 years). All patients were randomized and included in the safety and ITT 
analysis. Overall, 22 patients, 15 (20.3%) in the HA/CS group and 7 (19.4%) in the 
DMSO group, withdrew before the end of the study. 
A total of 88 patients, 61 for HA/CS and 27 for DMSO, were included in the PP 
population, mainly excluding patients who received grade A/B recommended 
treatments for BPS/IC within 3 months from inclusion or during the study.  
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Demographic and baseline clinical characteristics were comparable in the two 
treatment groups at baseline (Table I). Urinary frequency and bladder capacity 
appeared more severe in the DMSO group compared with the HA/CS group, but 
neither reached statistical significance.  
A significant reduction in pain intensity was observed at 6 months in both 
treatment groups versus baseline (P<0.0001) in the ITT population (Fig. 2A). Patients 
treated with HA/CS reported a greater mean VAS reduction compared with those 
treated with DMSO at 6 months (-39.15±29.14 versus -30.36±30.53, respectively), 
however, the between treatment group difference was not statistically significant (-
8.03; 95% CI -17.95, 1.88; P=0.1110) (Fig. 2A). The percentage of responders at 3 and 
6 months was also numerically higher for HA/CS compared with DMSO (70.27% 
versus 55.56% and 63.51% versus 55.56%, respectively) (Supporting Information 
Table I).  
Reduction in pain intensity at 6 months was significantly different between 
treatment groups in the PP population, with a mean VAS reduction of 44.77±25.07 
versus 28.89±31.14 for HA/CS versus DMSO, respectively (-13.34; 95% CI -24.399, -
2.283; P=0.0186) (Fig. 2B). There was also a higher percentage of responders for 
HA/CS compared with DMSO at both 3 and 6 months (77.05% versus 51.85% 
[P=0.025] and 72.13% versus 55.56% [P=not significant], respectively) (Supporting 
Information Table I). 
For secondary endpoints, both treatment groups showed significant 
improvements in pain reduction (Fig. 2A) and urination frequency at 3 months, and 
in ICSI/ICPI, PUF, and EQ-5D at 3 and 6 months (all P<0.0001 versus baseline) 
(Supporting Information Table II). Bladder capacity also improved significantly at 3 
Page 8 of 22
John Wiley & Sons
Neurourology & Urodynamics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9
months compared with baseline (P=0.0004) (Supporting Information Table II). There 
were no significant differences between treatment groups at 3 or 6 months for any 
of these parameters (Supporting Information Table II). 
AEs are summarized in Table II. A total of 52 and 39 AEs were reported in the 
HA/CS and DMSO groups, respectively, with 14.86% (11/74) and 30.56% (11/39) of 
patients reporting at least one AE, respectively (P=0.075). There were no differences 
in serious AEs or in the severity of AEs between groups. In the HA/CS group, 
treatment-related adverse events were seen in 1 of 74 patients (1.35%) with 1 event, 
compared with 8 of 36 patients (22.22%) with 12 events in the DMSO group 
(P=0.001). The most common treatment-related AEs were related to renal and 
urinary disorders, in particular bladder irritation or pain, cystitis, dysuria, and 
strangury (Table II). Lastly, it is important to note that 5.56% (2/36) of patients in the 
DMSO group discontinued treatment due to inefficacy compared with 2.70% (2/74) 
in the HA/CS group (P=0.596). 
Economic analyses (Table III) showed that when direct healthcare costs are 
considered, the ICER of HA/CS versus DMSO falls between 3735€/QALY (optimistic 
assumption) and 8003€/QALY (pessimistic assumption). Moreover, DMSO is more 
expensive than HA/CS when both direct and indirect costs are considered 
(18996.75€ versus 17865.38€, respectively). 
 
Discussion 
Improving the integrity of the urothelium through GAG substitution therapy 
is a valid approach for treatment of BPS/IC. Therapy with HA/CS has shown 
encouraging response rates(11, 12, 18, 26) as highlighted in a recent meta-
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analysis(27), and has received a high recommendation rating, according to the 
Centre for Evidence-Based Medicine(28) and EAU guidelines(29). The aim of this 
study was to compare the efficacy and safety of HA/CS with DMSO. 
In the ITT population, VAS pain reduction was significant in both groups. 
While numerically greater with HA/CS at both the end of treatment (59.93% versus 
48.00%, respectively) or after 3 months without any treatment (59.74% versus 
47.01%, respectively), the differences between groups in VAS pain reduction did not 
reach statistical significance. Of note, however, the efficacy results in the PP 
population, eliminating a possible confounding effect of any grade A/B 
recommended treatment for BPS/IC, showed a statistically significant difference in 
VAS pain reduction in favor of HA/CS (P=0.0186). 
The proportion of responders (50% VAS reduction from baseline) was 26.48% 
after 3 months and 14.31% after 6 months higher with HA/CS in the ITT population. 
In the PP population, this result was statistically significant at 3 months (P=0.025), 
with a 48.60% higher proportion of responders with HA/CS, which became 29.82% 
after 6 months. 
The efficacy of both HA/CS and DMSO is suggested based on the CSI/ICPI, 
PUF, and EQ-5D questionnaires alongside improvements in urination frequency and 
bladder capacity, although no significant differences between treatments were seen. 
The percentage of AEs was roughly twice that with DMSO and there were 
significantly fewer treatment-related AEs and fewer discontinuations for lack of 
efficacy with HA/CS. These results suggest that HA/CS has a more favorable safety 
profile than DMSO, although further studies are needed. 
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The results of the present study support the reduction in pain scores and 
urination frequency, as well as improvements in bladder capacity and quality of life, 
observed in previous smaller studies(11, 12, 18, 26). In addition, this study showed 
sustained pain reductions and improvement in all secondary endpoints at 3 months 
after treatment ended, suggesting that improvements are maintained over the long-
term. It would thus be of interest to further increase the follow-up time. 
Finally, economic evaluation showed an ICER (i.e. the cost of an additional life 
year in perfect health gained by HA/CS over DMSO) between 3735−8003€/QALY, 
which is well below commonly used thresholds indicating societies’ willingness to 
pay per QALY gained. Moreover, when a broader societal perspective is taken into 
account instead of the NHS one, DMSO is dominated by HA/CS. The limited amount 
of data available at the end of the study period reduces the validity of this analysis; 
however, the attempt to collect resource consumption and costs alongside clinical 
trials should be encouraged in the future in order to provide additional information 
that allows the identification of the cost-effectiveness profile of health technologies.  
One possible limitation of the present study is that it was not placebo-
controlled. However, the main objective was to compare the efficacy of HA/CS to 
currently-approved therapy, namely DMSO, and it was, nonetheless, randomized.  
 
Conclusions 
In conclusion, the present trial provides further support to previous data 
showing sustained improvement in symptoms following treatment of BPS/IC with 
HA/CS, in addition to subjective improvement in the quality of life and a more 
favorable safety profile compared with DMSO.  
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Figure legends.  
 
Fig. 1. CONSORT diagram of study. 
 
Fig. 2A. Mean change (95% CI) in pain VAS scores (0−100 mm) from baseline to 3 and 
6 months (ITT population, n=110). CI, confidence interval; ITT, intent to treat; VAS, 
visual analogue scale. 
Fig. 2B. Mean change (95% CI) in pain VAS scores (0−100 mm) from baseline to 3 and 
6 months (PP population, n=88). CI, confidence interval; PP, per protocol; VAS, visual 
analogue scale. 
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Fig. 2A. Mean change (95% CI) in pain VAS scores (0−100 mm) from baseline to 3 and 6 months (ITT 
population, n=110). CI, confidence interval; ITT, intent to treat; VAS, visual analogue scale.  
Fig. 2B. Mean change (95% CI) in pain VAS scores (0−100 mm) from baseline to 3 and 6 months (PP 
population, n=88). CI, confidence interval; PP, per protocol; VAS, visual analogue scale.  
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TABLE I. Demographic and Baseline Clinical Characteristics of Patients (ITT Population) 
 
Parameter HA/CS 
Mean (SD) 
DMSO 
Mean (SD) 
P value* 
Age, years 50.95 (14.97) 48.78 (17.70) 0.503 
BMI, kg/m
2
 23.26 (3.26) 23.27 (5.00) 0.988 
Years from diagnosis 2.97 (4.10) 3.96 (8.54) 0.654 
Pain VAS, mm 65.53 (21.00) 64.58 (20.53) 0.824 
Pain VAS, mm (PP population) 69.13 (17.11) 65.56 (20.05) 0.394 
ICSI score 12.47 (3.66) 12.72 (3.74) 0.733 
ICPI score 12.92 (2.76) 12.42 (3.02) 0.389 
PUF score 22.53 (5.25) 22.64 (5.38) 0.923 
EQ Index 0.25 (0.47) 0.26 (0.41) 0.921 
EQ VAS 54.36 (21.09) 59.09 (18.61) 0.262 
Urinary frequency 10.31 (4.12) 12.15 (5.55) 0.080 
Bladder capacity, mL 172.24 (96.54) 133.99 (65.46) 0.083 
* P values obtained using ANOVA. 
BMI, body mass index; CS, chondroitin sulfate; DMSO, dimethyl sulfoxide; EQ, EuorQol; HA, 
hyaluronic acid; ICPI, Interstitial Cystitis Problem Index; ICSI, Interstitial Cystitis Symptom 
Index; ITT, intent to treat; PP, per protocol; PUF, Pelvic Pain and Urgency/Frequency 
Symptom Scale; SD, standard deviation; VAS, visual analogue scale. 
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TABLE II. Summary of Adverse Events in the ITT population 
 
 HA/CS (N=74) DMSO (N=36)  
 Events n* (%) Events n* (%) P value** 
AEs 52 11 (14.86) 39 11 (30.56) 0.075 
Treatment-related AEs 1 1 (1.35) 12 8 (22.22) 0.001 
Instillation site odor 0 0 (0.0) 1 1 (2.78) 0.327 
Renal and urinary disorders 1 1 (1.35) 11 8 (22.22) 0.001 
Bladder irritation 0 0 (0.0) 1 1 (2.78) 0.327 
Bladder pain 1 1 (1.35) 1 1 (2.78) 0.550 
Cystitis 0 0 (0.0) 4 2 (5.56) 0.105 
Dysuria 0 0 (0.0) 4 4 (11.11) 0.010 
Strangury 0 0 (0.0) 1 1 (2.78) 0.327 
AEs leading to withdrawal 1 1 (1.35) 2 2 (5.56) 0.249 
Serious AEs 0 0 (0.0) 0 0 (0.0) - 
*Number of patients experiencing at least one AE during the study period. One patient could experience more than one adverse event. 
**Fisher’s exact test. 
AEs, adverse events; CS, chondroitin sulfate; DMSO, dimethyl sulfoxide; HA, hyaluronic acid; ITT, intent to treat. 
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TABLE III. Cost-effectiveness analyses results (ITT population).  
 
  DMSO HA/CS Δ ICER = €/QALY 
     Optimistic* Pessimistic** 
Costs Direct 398.37€ 538.43€ +140.06€ 3735.04€/QALY 8003.67€/QALY 
Direct & Indirect 18996.75€ 17865.38€ -1131.37€ DMSO dominated*** DMSO dominated*** 
Utility Baseline 0.26 0.25    
3 months 0.66 0.64    
6 months 0.58 0.65    
QALY Optimistic* 0.5600 0.5975 0.0375   
Pessimistic** 0.4800 0.4975 0.0175   
Direct costs include the cost of the visits (GP and specialists), instrumental and laboratory tests and additional pharmacological therapies 
assumed because of concomitant adverse events. Indirect costs include the cost of the productivity loss, informal care, domestic assistance, 
travels and accommodation.  
Δ, HA/CS-DMSO; QALY, Quality-Adjusted Life Year; ICER, Incremental Cost Effectiveness Ratio (∆Costs/ ∆QALY); ITT, intent to treat. 
* Scenario assuming the utility values measured at 6 months to hold until 12 months. 
** Scenario assuming the utility values to go back at the level observed at baseline from month 6 to 12 months. 
***DMSO is both less effective and more expensive than HA/CS when indirect costs are included in the analysis. 
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